Alkermes plc's phase III program with the antipsychotic ALKS 3831 for schizophrenia is designed to find out whether the tablet – which combines olanzapine with the firm's opioid antagonist samidorphan – can get around the weight-gain and metabolic problems that come with olanzapine by itself.